Dasatinib in solid tumors

Authors:
  • URUwe Rix
    Uwe Rix
  • EHEric B Haura
    Eric B Haura
Publisher website
Google Scholar
Abstract
Importance of the field: Dasatinib is an oral, potent adenosine triphosphate-competitive inhibitor of multiple tyrosine kinases including BCR-ABL, c-KIT, platelet-derived growth factor receptor, and Src family kinases (SFKs). It has gained much attention for its use in chronic myeloid leukemia and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. However, dasatinib is also being explored in solid tumors in ongoing Phase I and II clinical trials.Areas covered in this review: The clinical efficacy of dasatinib in a wide variety of solid tumors and important Phase I/II studies utilizing dasatinib and the optimal dosage used in solid tumors. A literature search was conducted using PubMed/MEDLINE, www.clinicaltrials.gov, and the American Society of Clinical Oncology websites to find relevant Phase I/II clinical trials during 1987 – 2009.What the reader will gain: The understanding that the biology and mechanism of Src activation in tumors are not well understood an...

This publication has 41 references indexed in Scilit: